Coordination of the NF-κB signaling pathway and lymphocyte metabolism in children with autoimmune diseases

Cover Page

Cite item

Full Text

Abstract

Metabolic aberrations underlie many chronic diseases, including autoimmune diseases (AUD). Immune metabolism is an area of immunological research that is actively developing and studying the processes of metabolic reprogramming in immune cells. The regulation of the nuclear factor kappa B (NF-κB) activity, which is involved in the coordination of innate and adaptive immunity, inflammatory reactions and other processes, is being actively studied. The studies on immune metabolism and regulation of NF-κB is a promising direction in searching for new therapeutic approaches in the AUD treatment. The aim of the present study was to evaluate the informative value of NF-κB and the activity of intracellular lymphocyte succinate dehydrogenase (SDH) and glycero-3-phosphate dehydrogenase (GPDH) determined in children with immune-dependent disorders. 350 children with autoimmune diseases were examined: 97 patients with IBD, 72 children with relapsing-remitting multiple sclerosis (MS), 83 pediatric patients with psoriasis vulgaris (PS), and 97 children with autoimmune hepatitis (AIH). The comparison group consisted of 100 conditionally healthy children. Activity of mitochondrial dehydrogenases, i.e., SDH and GPDH, was evaluated by immunocytochemical method. The levels of NF-κB translocation (per cent of cells with NF-κB translocation from cytoplasm to cell nucleus) was determined by flow cytometry, with visualization. Statistical evaluation and plotting were carried out using the Statistica 13.0 software. The highest activity of SDH and GPDH was detected in the population of cytotoxic T lymphocytes and T helper cells, and the lowest activity of the enzymes was registered in the population of B lymphocytes, both in children with AUD and in comparison group. In children with AUD, there was a significant decrease in SDH activity in T lymphocytes, cytotoxic T lymphocytes, B lymphocytes and NK cells against the comparison group (p < 0.01). In children with PS, AIH and IBD, a decrease in SDH activity was revealed in Treg and Th17 cells. The most pronounced decrease in GPDH was characteristic of patients with AH (in T cells, cytotoxic T lymphocytes, B cells, NK cells and Tregs against the comparison group). In children with PS, the activity of GPDH was reduced only in Tregs (p < 0.05). For children with multiple sclerosis, a decrease in GPDH was revealed in populations of T lymphocytes, B lymphocytes and activated T helpers (p < 0.01). In the group of patients with IBD, there were no significant differences in the activity of GPDG relative to the comparison group. A significant increase in the level of NF-κB translocation in T helpers was revealed in all children with AUD relative to the comparison group. In children with AIH and PS, a significant increase in the level of NF-κB translocation was revealed in Treg, Thact and Th17 cells, in children with MS it was found in Treg cells, in patients with IBD, it was registered in Thact against the comparison group (p < 0.05). An inverse correlation was found between the levels of NF-κB translocation in lymphocyte populations, and activity of mitochondrial dehydrogenases in the lymphocytes. The most significant dependencies are characteristic of NK cells and T cell populations, and these correlations are valid for all groups of AUD patientsh. In the course of in vitro experiments with a drug of metabolic action, a decreased number of cells with NF-κB translocation and an increased SDH activity was observed; the degree of SDH activation depended on the cell population type, the greatest changes were detectable in the population of T lymphocytes (by 61%), in B lymphocytes (by 30%), in NK cells (by 19%). The study of the metabolic activity of lymphocytes and the NF-κB signaling pathway allows us to assess the general mechanisms of immunopathological processes in children with autoimmune diseases of various etiologies. As based on the inverse correlation between the level of translocation of NF-κB and the activity of SDH in lymphocytes, one may consider the use of an available immunocytochemical method being an analogue for assessing activity of the NF-κB transcription factor. The studies of immune metabolic correction of immunocompetent cells are a promising direction in the AUD treatment.

About the authors

Olga V. Kurbatova

National Medical Research Center for Children’s Health

Author for correspondence.
Email: putintseva@mail.ru
ORCID iD: 0000-0002-9213-5281

PhD (Medicine), Senior Research Associate, Laboratory of Experimental Immunology and Virology, National Medical Research Center for Children’s Health

Russian Federation, Moscow

T. V. Radygina

National Medical Research Center for Children’s Health

Email: tvradigina@mail.ru
ORCID iD: 0000-0003-4704-6885

PhD (Medicine), Senior Research Associate, Laboratory of Experimental Immunology and Virology, National Medical Research Center for Children’s Health

Russian Federation, Moscow

D. G. Kuptsova

National Medical Research Center for Children’s Health

Email: dg.kuptsova@gmail.com
ORCID iD: 0000-0001-7771-3314

Junior Research Associate, Clinical Laboratory Doctor, Laboratory of Experimental Immunology and Virology, National Medical Research Center for Children’s Health

Russian Federation, Moscow

S. V. Petrichuk

National Medical Research Center for Children’s Health

Email: cito@list.ru
ORCID iD: 0000-0003-0896-6996

PhD, MD (Biology), Professor, Chief Research Associate, Laboratory of Experimental Immunology and Virology, National Medical Research Center for Children’s Health

Russian Federation, Moscow

G. B. Movsisyan

National Medical Research Center for Children’s Health

Email: movsisyan@nczd.ru
ORCID iD: 0000-0003-2881-4703

PhD (Medicine), Senior Research Associate, Laboratory of Rare Hereditary Diseases, Gastroenterologist of the Gastroenterology Department with the Hepatological Group, National Medical Research Center for Children’s Health

Russian Federation, Moscow

A. S. Potapov

National Medical Research Center for Children’s Health; I. Sechenov First Moscow State Medical University (Sechenov University)

Email: potapov@nczd.ru
ORCID iD: 0000-0003-4905-2373

PhD, MD (Medicine), Professor, Chief Scientist, Laboratory of Scientific Foundations of Pediatric Gastroenterology and Hepatology, Head, Gastroenterology Department with Hepatology Group, National Medical Research Center for Children’s Health; Professor, Department of Pediatrics and Pediatric Rheumatology, I. Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow; Moscow

N. N. Murashkin

National Medical Research Center for Children’s Health; I. Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy of Department of Presidential Affairs

Email: m_nn2001@mail.ru
ORCID iD: 0000-0003-2252-8570

PhD, MD (Medicine), Head, Department of Dermatology with the Laser Surgery Group, Head of the Laboratory of Skin Pathology in Children at the Department of Pediatric Research, National Medical Research Center for Children’s Health; Professor, Department of Dermatovenerology and Cosmetology, Central State Medical Academy of Department of Presidential Affairs; Professor, Department of Pediatrics and Pediatric Rheumatology, I. Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow; Moscow; Moscow

L. M. Abdullaeva

National Medical Research Center for Children’s Health

Email: instorm@inbox.ru
ORCID iD: 0000-0003-1574-2050

Junior Research Associate, Laboratory of Rare Hereditary Diseases in Children of the Medical Genetic Center; Neurologist, Department of Psychoneurology and Psychosomatic Pathology, National Medical Research Center for Children’s Health

Russian Federation, Moscow

A. P. Fisenko

National Medical Research Center for Children’s Health

Email: fisenko@nczd.ru
ORCID iD: 0000-0001-8586-7946

PhD, MD (Medicine), Professor, Head, National Medical Research Center for Children’s Health

Russian Federation, Moscow

References

  1. Купцова Д.Г., Петричук С.В., Мурашкин Н.Н., Курбатова О.В., Радыгина Т.В., Хотко А.А., Иванов Р.А. Активность ядерного фактора транскрипции B в популяциях лимфоцитов у детей c псориазом // Вестник РГМУ, 2022. № 2. С. 30-38. [Kuptsova D.G., Petrichuk S.V., Murashkin N.N., Kurbatova O.V., Radygina T.V., Khotko A.A., Ivanow R.A. Activity of nuclear factor B in lymphocyte populations of children with psoriasis. Vestnik RGMU = Bulletin of Russian State Medical University, 2022, no. 2, pp. 28-35. (In Russ.)]
  2. Курбатова О.В., Купцова Д.Г., Закиров Р.Ш., Радыгина Т.В., Мовсисян Г.Б., Фрейдлин Е.В., Семикина Е.Л., Потапов А.С., Мурашкин Н.Н., Петричук С.В. Перспективы изучения иммунометаболизма в клинической практике // Вестник Ташкентской медицинской академии, 2023. № 3 (1). С. 98-104. [Kurbatova O.V., Kuptsova D.G., Zakirov R.Sh., Radygina T.V., Movsisyan G.B., Freidlin E.V., Semikina E.L., Potapov A.S., Murashkin N.N., Petrichuk S.V. Prospects for the study of immunometabolism in clinical practice. Vestnik Tashkentskoy meditsinskoy akademii = Bulletin of the Tashkent Medical Academy, 2023, no. 3 (1), pp. 98-104. (In Russ.)]
  3. Петричук С.В., Радыгина Т.В., Купцова Д.Г., Курбатова О.В., Семикина Е.Л., Мурашкин Н.Н., Потапов А.С., Фисенко А.П. Оценка эффективности анти-TNF терапии у детей с иммунозависимыми заболеваниями по активности NF-B в популяциях лимфоцитов // Российский иммунологический журнал, 2022. Т. 25, № 4. С. 491-498. [Petrichuk S.V., Radygina T.V., Kuptsova D.G., Kurbatova O.V., Semikina E.L., Murashkin N.N., Potapov A.S., Fisenko A.P. Evaluation of anti-TNF treatment efficiency in children with immune-dependent diseases by means of testing the NF-B activity in lymphocyte populations. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2022, Vol. 25, no. 4, pp. 491-498. (In Russ.)] doi: 10.46235/1028-7221-1191-EOA.
  4. Andres-Ejarque R., Ale H.B., Grys K., Tosi I., Solanky S., Ainali C., Catak Z., Sreeneebus H., Saklatvala J., Dand N., de Rinaldis E., Chapman A., Nestle F.O., Barnes M.R., Warren R.B., Reynolds N.J., Griffiths C.E.M., Barker J.N., Smith C.H., di Meglio P.; PSORT Consortium. Enhanced NF-B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nat. Commun., 2021, Vol. 12, no. 1, 4741. doi: 10.1038/s41467-021-25066-9.
  5. Angajala A., Lim S., Phillips J.B., Kim J.H., Yates C., You Z., Tan M. Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism. Front. Immunol., 2018, Vol. 9, 1605. doi: 10.3389/fimmu.2018.01605.
  6. Chen X., Sunkel B., Wang M., Kang S., Wang T., Gnanaprakasam J.N.R., Liu L., Cassel T.A., Scott D.A., Muñoz-Cabello A.M., Lopez-Barneo J., Yang J., Lane A.N., Xin G., Stanton B.Z., Fan T.W., Wang R. Succinate dehydrogenase/complex II is critical for metabolic and epigenetic regulation of T cell proliferation and inflammation. Sci. Immunol., 2022, Vol. 7, no. 70, eabm8161. doi: 10.1126/sciimmunol.abm8161.
  7. Conrad N., Misra S., Verbakel J.Y., Verbeke G., Molenberghs G., Taylor P.N., Mason J., Sattar N., McMurray J.J.V., McInnes I.B., Khunti K., Cambridge G. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet, 2023, Vol. 401, no. 10391, pp. 1878-1890.
  8. Iacobazzi D., Convertini P., Todisco S., Santarsiero A., Iacobazzi V., Infantino V. New insights into NF-B signaling in innate immunity: focus on immunometabolic crosstalks. Biology (Basel), 2023, Vol. 12, no. 6, 776. doi: 10.3390/biology12060776.
  9. Kedia-Mehta N., Finlay D.K. Competition for nutrients and its role in controlling immune responses. Nat. Commun., 2019, Vol. 10, no. 1, 2123. doi: 10.1038/s41467-019-10015-4.
  10. Ma R., Ji T., Zhang H., Dong W., Chen X., Xu P., Chen D., Liang X., Yin X., Liu Y., Ma J., Tang K., Zhang Y., Peng Y., Lu J., Zhang Y., Qin X., Cao X., Wan Y., Huang B. A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells. Nat. Cell Biol., 2018, Vol. 20, no. 1, pp. 21-27.
  11. Pucino V., Guma M. Editorial: The role of immunometabolism in autoimmune mediated and autoinflammatory disorders. Front. Immunol., 2022, Vol. 13, 969939. doi: 10.3389/fimmu.2022.969939.
  12. Rothschild D.E., McDaniel D.K., Ringel-Scaia V.M., Allen I.C. Modulating inflammation through the negative regulation of NF-B signaling. J. Leukoc. Biol., 2018, 10.1002/JLB.3MIR0817-346RRR. doi: 10.1002/JLB.3MIR0817-346RRR.
  13. Sharfe N., Dalal I., Naghdi Z., Lefaudeux D., Vong L., Dadi H., Navarro H., Tasher D., Ovadia A., Zangen T., Ater D., Ngan B., Hoffmann A., Roifman C.M. NFB pathway dysregulation due to reduced RelB expression leads to severe autoimmune disorders and declining immunity. J. Autoimmun., 2023, Vol. 137, 102946. doi: 10.1016/j.jaut.2022.102946.
  14. Sun S.C., Chang J.H., Jin J. Regulation of nuclear factor-B in autoimmunity. Trends Immunol., 2013, Vol. 34, no. 6, pp. 282-289.
  15. van den Bossche J., Horng T., Ryan D.G. Immunometabolism at the basis of health and disease; an editorial. Biochim. Biophys. Acta Mol. Basis Dis., 2023, Vol. 1869, no. 6, 166715. doi: 10.1016/j.bbadis.2023.166715.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure 1. Dependence of SDH activity and the level of NF-B translocation in lymphocytes in children with psoriasis (A), autoimmune hepatitis (B), inflammatory bowel disease (C), and multiple sclerosis (D)

Download (617KB)

Copyright (c) 2023 Kurbatova O.V., Radygina T.V., Kuptsova D.G., Petrichuk S.V., Movsisyan G.B., Potapov A.S., Murashkin N.N., Abdullaeva L.M., Fisenko A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».